The FDA has converted the accelerated approval of rucaparib to full approval for certain patients with metastatic castration-resistant prostate cancer. The U.S. Food and Drug Administration (FDA) has granted traditional approval to rucaparib (Rubraca)...
Fam-trastuzumab deruxtecan-nxki (T-DXd) with pertuzumab was approved to treat metastatic HER2-positive breast cancer. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for patients with...
Clinical trial presented at SABCS finds some patients may safely skip sentinel lymph node biopsy.
In clinical trials presented at SABCS, a mobile health tool and acupuncture helped to improve breast cancer survivors' quality of life.
The FDA approved a combination of the PARP inhibitor niraparib with a hormone therapy agent plus a corticosteroid for certain patients with metastatic prostate cancer. The U.S. Food and Drug Administration (FDA) has approved...
The addition of targeted therapy helps control metastatic breast cancer, and a pair of immunotherapy drugs prolongs survival in multiple myeloma.
Amid the debate over menopausal hormone therapy and cancer risk, researchers at SABCS provided some clarity for women with BRCA1/2 mutations.
SABCS educational session highlights how alcohol and obesity can raise the risk for breast cancer.
Throughout the years, SABCS has shown how tucatinib has progressed into a potential frontline therapy for HER2-positive breast cancer.
New insights into the neurologic and physiologic impact of chronic stress on ovarian cancer were presented at two recent AACR conferences.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More